Wells Fargo resumed coverage of Procept BioRobotics (PRCT) with an Overweight rating and $112 price target The firm believes aquablation remains early stages in its adoption, which will be further supported by a new product cycle, the analyst tells investors in a research note. Procept is comfortable with 2025 consensus estimates, Wells says, adding that the firm is receiving “generally positive” physician feedback on Hydros.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics initiated with an Overweight at Morgan Stanley
- Procept BioRobotics initiated with a Hold at Jefferies
- PROCEPT BioRobotics (PRCT) Continues to Invest in Labor-Saving Robotics
- Procept BioRobotics price target raised to $105 from $95 at Truist
- Procept BioRobotics 1.92M share Spot Secondary priced at $91.00